Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718956 | 1.00 | GPR119 (0.48) | GPR119MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3702657 | 1.00 | GPR119 (0.48) | GPR119MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3692561 | 0.89 | GPR119 (0.63) | GPR119 | |
| SCHEMBL3692557 | 0.89 | GPR119 (0.63) | GPR119 | |
| SCHEMBL3698661 | 0.89 | GPR119 (0.63) | GPR119 | |
| SCHEMBL2717223 | 0.87 | GPR119 (0.48) | GPR119MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2716213 | 0.85 | GPR119 (0.50) | GPR119MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2729167 | 0.80 | GPR119 (0.64) | GPR119MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2716793 | 0.80 | GPR119 (0.64) | GPR119MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2716792 | 0.80 | GPR119 (0.64) | GPR119MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772302-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-08 | — | — | US | claimed |
| EP-2445904-B1 | 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2013-09-11 | — | — | EP | claimed |
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2012-05-17 | — | — | US | claimed |
| US-8772302-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-08 | — | — | US | disclosed |
| EP-2445904-B1 | 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2013-09-11 | — | — | EP | disclosed |
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2012-05-17 | — | — | US | disclosed |
| EP-2445904-A1 | NOVEL GPR 119 AGONISTS | Cadila Healthcare Limited (IN) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010146605-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | GPR119, GPR4, GPR39 | GPR119 1/4885MEN1 4364/4885KMT2A 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.